If you want to understand what’s wrong with Washington, look no further than the latest scheme from the Centers for Medicare and Medicaid Services (CMS). Behind closed doors, unelected bureaucrats are pushing an expansion of the so-called Competitive Bidding Program, a move that doesn’t just hurt patients, but hands America’s healthcare supply chain over to Beijing.
This is more than just bad policy. It is a direct attack on the America First healthcare agenda President Trump fought to advance.
President Trump’s goal was always clear: protect Medicare, reduce bureaucratic interference, and expand access to innovative, personalized care. He stood up to the rigged systems that punished patients and rewarded red tape. In 2020, Trump signed an executive order to expand access to new medical devices for seniors, stating “we want Medicare beneficiaries to get the latest treatments without delay.”
However, CMS is now moving in the opposite direction. The agency is proposing to expand competitive bidding into new categories of essential supplies, including urological, ostomy, and tracheostomy equipment. These aren’t interchangeable commodities. These are highly personalized medical lifelines that seniors, veterans, and people with disabilities depend on every single day.
On paper, competitive bidding looks like cost cutting. In reality, it means Medicare contracts only with suppliers who can offer the lowest possible bids. That sounds efficient until you realize what it really means: patients lose choice, quality goes down, and small American suppliers get driven out.
History tells us what comes next: Chinese manufacturers flood the market with cheap, inferior products. We’ve seen this play out across industries, from steel to pharmaceuticals. Healthcare equipment cannot become another casualty. When America depends on Beijing for catheters or tracheostomy supplies, that’s not fiscal conservatism, it’s a national security risk.
The hardest hit will be small, local, and family-run medical suppliers who provide the kind of service and education that big national chains, and certainly foreign importers, cannot match. These companies are lifelines for patients in rural and underserved communities. If CMS succeeds, many of them will be wiped out.
Patients won’t just lose trusted suppliers: they’ll lose the dignity of having care tailored to their individual needs. Instead, they’ll be forced to accept a “lowest common denominator” product, chosen not by doctors or patients, but by Washington spreadsheets.
Who will win? Not patients. Not caregivers. Not American small businesses.
The only winners are federal agencies looking to cut costs at any price, and foreign suppliers eager to corner yet another U.S. market.
If Congress allows this rule to go forward, it won’t stop here. Today, it’s catheters and ostomy supplies. Tomorrow, it could be insulin pumps, pacemakers, or even cancer treatments. Once the precedent is set, bureaucrats can apply the same flawed logic to anything.
Lawmakers who support President Trump’s healthcare agenda must act now. Hold hearings. Demand answers from CMS. And stop this reckless rule before it undermines patient care and surrenders our medical supply chain to Beijing.
President Trump stood for choice, innovation, and dignity in healthcare. This rule undermines all three, while making America dangerously dependent on China. Let’s not allow a few unelected bureaucrats to dismantle his legacy and hand the future of American healthcare to Beijing.
